Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Verrica Pharmaceuticals Inc. (VRCA) had Revenue of $7.57M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$7.57M
Net Income	$-76.58M
Cost of Goods Sold	$2.74M
Gross Profit	$4.83M
Operating Expenses	$73.48M
Operating Income	$-65.92M
Non-Operating Income/Expense	$-10.66M
Pre-Tax Income	$-76.58M
Normalized Pre-Tax Income	$-76.58M
Income after Taxes	$-76.58M
Income from Continuous Operations	$-76.58M
Consolidated Net Income/Loss	$-76.58M
Normalized Income after Taxes	$-76.58M
EBIT	$-65.92M
EBITDA	$-64.65M
Weighted-Average Shares Outstanding (Basic)	51.81M
Weighted-Average Shares Outstanding (Diluted)	51.81M
Earnings per Share (EPS) (Basic)	$-1.48
Earnings per Share (EPS) (Diluted)	$-1.48
Balance Sheet Financials
Current Assets	$51.18M
Property, Plant, and Equipment	$0.59M
Long-Term Assets	$2.96M
Total Assets	$54.13M
Current Liabilities	$29.01M
Long-Term Debt	$31.75M
Long-Term Liabilities	$34.98M
Total Liabilities	$63.99M
Common Equity	$-9.86M
Tangible Shareholders Equity	$-9.86M
Shareholders Equity	$-9.86M
Common Shares Outstanding	91.78M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-60.93M
Cash Flow from Investing Activities	$-0.02M
Cash Flow from Financial Activities	$37.73M
Beginning Cash	$69.55M
End Cash	$46.33M
Increase/Decrease in Cash	$-23.22M
Stock-Based Compensation	$7.16M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.76
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.45
Debt to Equity Ratio	-4.57
Gross Margin	63.79%
Operating Margin	-871.25%
EBIT Margin	-871.25%
EBITDA Margin	-854.48%
Pre-Tax Profit Margin	-1012.15%
Profit Margin	-1012.15%
Free Cash Flow	$-60.95M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.14
Inventory Turnover	1.11
Receiveable Turnover	98.26
Days Sales in Receivables	3.71
Return on Equity	776.66%
Return on Tangible Equity	776.66%
Return on Assets	-141.46%
Return on Investments	-349.82%
Book Value Per Share	$-0.11
Free Cash Flow per Share	$-1.18
Operating Cash Flow per Share	$-1.18

Data from Zacks Investment Research, Inc.